Successful Partnership Between MAIA Biotechnology and Cromos Pharma
MAIA Biotechnology and Cromos Pharma have partnered up in an innovative collaboration to advance cancer treatment. Mutual collaborative efforts are focused on THIO, a groundbreaking telomere-targeting agent for non-small cell lung cancer (NSCLC). In a trial presented at ASCO 2024, THIO demonstrated an impressive 85% disease control rate.
Read more in the press release: https://www.pr.com/press-release/914337
